“We are re-establishing estimates, a Buy rating and $14.00 PT for Flex Pharma. Flex is developing FLX-787, an innovative anti-cramp drug in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) and multiple sclerosis (MS). We believe CMT , on which we base our PT , has the highest chance of success. We anticipate Ph2 data in 1Q’18 (MS) and 3Q’18 (ALS, CMT). In 2Q’16, Flex launched HOTSHOT , a consumer beverage for exercise- associated muscle cramps that works via the same mechanisms as FLX-787.”,” the firm’s analyst commented.
Other equities analysts have also issued reports about the company. Needham & Company LLC raised their price target on Boston Scientific Corporation from $30.00 to $32.00 and gave the stock a buy rating in a report on Thursday, June 22nd. BMO Capital Markets reaffirmed a buy rating and issued a $30.00 price target on shares of Boston Scientific Corporation in a report on Wednesday, June 21st. Zacks Investment Research raised Boston Scientific Corporation from a hold rating to a buy rating and set a $31.00 price target for the company in a report on Wednesday, June 28th. BidaskClub lowered Boston Scientific Corporation from a strong-buy rating to a buy rating in a report on Thursday, July 6th. Finally, Royal Bank Of Canada reaffirmed a buy rating and issued a $31.00 price target on shares of Boston Scientific Corporation in a report on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Boston Scientific Corporation presently has an average rating of Buy and a consensus target price of $29.88.
Boston Scientific Corporation (NYSE BSX) opened at 28.79 on Thursday. The firm has a 50-day moving average price of $27.06 and a 200 day moving average price of $26.38. Boston Scientific Corporation has a one year low of $19.67 and a one year high of $29.08. The firm has a market capitalization of $39.50 billion, a PE ratio of 51.50 and a beta of 1.09.
Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same period last year, the company earned $0.27 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. Analysts anticipate that Boston Scientific Corporation will post $1.26 EPS for the current fiscal year.
WARNING: “Jefferies Group LLC Reaffirms Hold Rating for Boston Scientific Corporation (BSX)” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://sportsperspectives.com/2017/09/10/jefferies-group-llc-reaffirms-hold-rating-for-boston-scientific-corporation-bsx.html.
In other Boston Scientific Corporation news, SVP Wendy Carruthers sold 12,433 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $26.75, for a total transaction of $332,582.75. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP John Bradley Sorenson sold 2,100 shares of the firm’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $27.15, for a total value of $57,015.00. Following the sale, the senior vice president now owns 18,880 shares in the company, valued at approximately $512,592. The disclosure for this sale can be found here. Insiders have sold 275,257 shares of company stock worth $7,512,394 in the last 90 days. Company insiders own 0.74% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BSX. BB&T Corp raised its position in Boston Scientific Corporation by 28.9% during the first quarter. BB&T Corp now owns 12,577 shares of the medical equipment provider’s stock valued at $313,000 after purchasing an additional 2,817 shares in the last quarter. Commerzbank Aktiengesellschaft FI increased its holdings in shares of Boston Scientific Corporation by 39.6% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 31,506 shares of the medical equipment provider’s stock worth $784,000 after buying an additional 8,939 shares during the period. Xact Kapitalforvaltning AB increased its holdings in shares of Boston Scientific Corporation by 5.6% in the first quarter. Xact Kapitalforvaltning AB now owns 221,571 shares of the medical equipment provider’s stock worth $5,510,000 after buying an additional 11,808 shares during the period. Pictet Asset Management Ltd. increased its holdings in shares of Boston Scientific Corporation by 1.6% in the first quarter. Pictet Asset Management Ltd. now owns 1,219,677 shares of the medical equipment provider’s stock worth $30,333,000 after buying an additional 18,900 shares during the period. Finally, LS Investment Advisors LLC increased its holdings in shares of Boston Scientific Corporation by 14.0% in the first quarter. LS Investment Advisors LLC now owns 38,847 shares of the medical equipment provider’s stock worth $966,000 after buying an additional 4,763 shares during the period. Institutional investors and hedge funds own 90.52% of the company’s stock.
About Boston Scientific Corporation
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.